报价延迟最少15分钟:2026/03/28 19:09 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.34 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.02/-0.12
|
|
企业价值
420.60M
|
| 资产负债 |
|
每股账面净值
0.12
|
| 现金流量 |
|
现金流量率
0.19
|
| 损益表 |
|
收益
236.20M
|
|
每股收益
0.75
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development. |
